Encoding gene of EHD2 polypeptide, vector and medical application thereof

Through gene recombination technology, EHD2 polypeptide encoding genes and vectors were constructed, and using its autophagy and promoting lipid metabolism function, anti-non-alcoholic fatty liver drugs were developed, solving the problem of lack of effective treatment of NAFLD in the prior art, and realizing the liver The significant autophagy and lipid metabolism functions in cells have important clinical application prospects.

CN118956884AInactive Publication Date: 2024-11-15NANTONG UNIV

Patent Information

Application Number
CN202411099653.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art lacks effective drugs for the treatment of non-alcoholic fatty liver disease (NAFLD), and the pathogenesis is not fully elucidated, mainly relying on lifestyle interventions and physical exercise.

Method used

Through gene recombination technology, the encoding genes and vectors of EHD2 polypeptides are constructed, and the autophagy of EHD2 polypeptides and the promotion of lipid metabolism function are used to develop anti-non-alcoholic fatty liver drugs, which can promote autophagy of HepG2 cells and inhibit lipid accumulation in hepatocytes and inhibit lipid accumulation in hepatocytes. Lipid synthesis.

Benefits of technology

The recombinant expression and functional verification of EHD2 polypeptide was achieved, showing that it has significant autophagy and promotes lipid metabolism in hepatocytes, and has important development and application prospects for the clinical treatment of non-alcoholic fatty liver.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956884A_ABST
    Figure CN118956884A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of bioengineering, and discloses a coding gene of EHD2 polypeptide, a carrier and medical application of the EHD2 polypeptide. The amino acid sequence of the EHD2 polypeptide is as shown in SEQ ID NO. 1, and the DNA sequence of the coding gene is as shown in SEQ ID NO. 2. The EHD2 polypeptide has the important functions of autophagy and lipid metabolism promotion, and the EHD2 polypeptide, the coding gene and the carrier can be applied to preparation of drugs for resisting non-alcoholic fatty liver, and drugs for inhibiting lipid synthesis in hepatocytes and promoting lipid metabolism by promoting HepG2 cell autophagy and / or inhibiting hepatocyte lipid accumulation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of bioengineering, and specifically relates to an EHD2 polypeptide encoding gene, a vector and medical use thereof. Background Art

[0002] Non-alcoholic fatty liver disease is mainly characterized by fatty degeneration of the liver and is the most common chronic liver disease in the world. Fatty degeneration of the liver is only the first step of NAFLD. If it is not controlled, it can gradually develop into non-alcoholic fatty liver disease, fibrosis and hepatocellular carcinoma. It can also lead to disorders of blood sugar and lipid metabolism, causing a series of metabolic diseases such as diabetes, hypertension, and coronary heart disease. NAFLD is a complex disease, and its pathogenesis has not yet been further elucidated. There is still no drug specifically for the treatment of NAFLD, and lifestyle intervention and increased physical exercise are still the main treatments. Summary of the invention

[0003] In view of the deficiencies in the prior art, the present invention aims to provide a gene encoding an EHD2 polypeptide, a vector and its medical use. The gene encoding an EHD2 polypeptide and the vector have the important functions of autophagy and promoting lipid metabolism.

[0004] In a first aspect of the present invention, a gene encoding an EHD2 polypeptide is provided, wherein the amino acid sequence of the EHD2 polypeptide is shown as SEQ ID NO.1, and the DNA sequence of the gene is shown as SEQ ID NO.2.

[0005] The second aspect of the present invention provides a vector of EHD2 polypeptide, characterized in that the DNA sequence of EHD2 polypeptide is connected to the PCMV-HA eukaryotic expression vector to construct a recombinant expression plasmid, namely the vector.

[0006] The third aspect of the present invention provides an application of an EHD2 polypeptide, a gene encoding an EHD2 polypeptide, or a vector containing an EHD2 polypeptide in the preparation of an anti-non-alcoholic fatty liver disease drug, wherein the amino acid sequence of the EHD2 polypeptide is shown in SEQ ID NO.1, and the DNA sequence of the gene is shown in SEQ ID NO.2.

[0007] Furthermore, the anti-nonalcoholic fatty liver drug is a drug that inhibits lipid synthesis in hepatocytes and promotes lipid metabolism by promoting HepG2 cell autophagy and / or inhibiting hepatocyte lipid accumulation.

[0008] Compared with the prior art, the present invention utilizes bioengineering technology to genetically recombinant a DNA sequence corresponding to an EHD2 polypeptide into a pcDNA3.1 eukaryotic expression vector. After enzyme digestion and sequence analysis prove that the recombination is successful, the eukaryotic expression recombinant polypeptide is transfected into liver cells, and immunoblotting proves the protein expression of the polypeptide, achieving the recombination of the polypeptide, and studying the lipid metabolism promoting function of the polypeptide. Cellular and in vivo mouse experiments show that the EHD2 polypeptide has the important functions of autophagy and promoting lipid metabolism, and has a very important development and application prospect for the clinical treatment of non-alcoholic fatty liver disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] In order to more clearly illustrate the specific implementation methods of the present application or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0010] Figure 1 This is a graph showing the expression results of the EHD2 polypeptide detected in Example 1 of the present invention;

[0011] Figure 2 It is the electron microscopic result of the EHD2 polypeptide eukaryotic expression experimental group and the control group in Example 2 of the present invention;

[0012] Figure 3 It is a representative picture of the experimental group and the control group of the EHD2 polypeptide eukaryotic expression after Oil Red staining of HepG2 cells treated with oleic acid (OA) in Example 2 of the present invention (upper figure), and the statistical analysis of the difference in the level of lipid accumulation by Oil Red staining (lower figure; ***, P<0.001, statistically significant);

[0013] Figure 4 WB experiments detected that EHD2 polypeptide has an inhibitory effect on the expression of lipid accumulation regulatory protein SREBP1. DETAILED DESCRIPTION

[0014] The present application will be further described below in conjunction with the embodiments and examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. In addition, it should be understood that after reading the content taught in the present application, those skilled in the art may make various changes or modifications to the present application, and these equivalent forms also fall within the protection scope of the claims attached to the present application.

[0015] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0016] The present invention will be further described below in conjunction with specific embodiments.

[0017] Example 1 EHD2 polypeptide recombinant

[0018] Extract human mRNA, reverse transcribe into cDNA, use cDNA as template, design corresponding upstream and downstream primers, and successfully amplify the corresponding cDNA coding sequence by PCR technology, as shown in SEQ ID NO.2. The amino acid sequence of the EHD2 polypeptide expressed by the sequence is shown in SEQ ID NO.1. Connect the amplified fragment with the vector, obtain the recombinant plasmid through transformation, extraction and other steps, and then identify by enzyme digestion and sequence. The amino acid sequence of the EHD2 polypeptide and the corresponding cDNA coding sequence are shown in SEQ ID NO.1 and SEQ ID NO.2.

[0019] The amino acid sequence of the EHD2 polypeptide in the present application is shown in the sequence listing SEQ ID NO.1, and is as follows:

[0020] SEQ ID NO.1:

[0021] 1 EAEWVVTKDK SKYDE I FYNL APADGKLSGS KAKTWMVGTK

[0022] 41 LPNSVLGRIW KLSDVDRDGM LDDEEFALAS HL I EAKLEGH

[0023] 81 GLPANLPRRL VPPSKRRHKG

[0024] The coding gene of the EHD2 polypeptide in the present application is shown in the sequence list SEQ ID NO.2, which is as follows:

[0025] SEQ ID NO.2:

[0026] gaagcagagtgggtagtcactaaggataagagcaagtatgacgaaattttctacaatcttgcccctgc

[0027] cgatgggaagttgtccgggagtaaggctaaaacctggatggttggcaccaaactccccaattctgtac

[0028] tcggacggatatggaaactctccgatgtcgaccgggatggcatgcttgacgatgaagagtttgcattg

[0029] gcgagccacctgatcgaagctaaacttgaaggtcacggcctgccagctaacttgccccgacgcctggt

[0030] gccgccctctaaacgacgccataagggc

[0031] After the plasmid containing the polypeptide nucleic acid fragment was double-digested with ECOR1 and BamH1, the fragment was obtained using a recovery kit, and the plasmid pcDNA3.1 (about 5kbp) was treated with the same double digestion, and then the recovered polypeptide nucleic acid fragment and the digested vector pcDNA3.1 were connected overnight at 16°C under the action of T4 DNA ligase. Take 2μl of the ligation product and incubate it with 40μl of DH5α competent cells on ice. After the incubation, heat shock treatment was performed at 42°C for 90 seconds, and then immediately placed on ice for 3 minutes, followed by adding 300μl of LB medium without antibiotics to mix. Recover on a 37°C shaker for 45 minutes, then apply 150μl of the bacterial solution directly to the LB culture dish with ampicillin antibiotics and incubate overnight at 37°C. After the incubation, individual full colonies were picked and inoculated into 5 ml of LB medium containing 50 μg / ml ampicillin, and cultured on a shaker at 37°C for 16 h. The obtained bacterial solution was directly sequenced to identify positive clones overexpressing the EHD2 polypeptide.

[0032] The correctly connected EHD2 polypeptide eukaryotic expression vector was transfected into HepG2 cells, and samples were collected after 48 hours. The treated cells were collected and lysed with immunoprecipitation buffer (1mL RIPA + 20μL PMSF + 80μL protease inhibitor PI). Note that all operations should be performed on ice. Discard the old culture medium, wash with PBS 2-3 times, add an appropriate amount of cell lysis buffer to the culture plate and place it on ice for 30 minutes; grind the culture plate on ice with an enzyme-free cell scraper, and transfer the lysis buffer mixed with cell fragments into a pre-labeled 1.5mL EP tube; record the volume of the transferred lysis buffer, add Loading Buffer at a ratio of 4:1, heat in a metal bath at 100℃ for 15 minutes, and then store the tissue sample in a -80 ultra-low temperature refrigerator. The immunoblotting experiment was carried out through a series of steps such as electrophoresis, membrane transfer, blocking, antibody incubation, and development. The results showed that the immunoblotting results proved the expression of this polypeptide, such as Figure 1 As shown, the size is 12KD.

[0033] Example 2 Detection of the anti-lipid accumulation function of EHD2 polypeptide

[0034] Experiments have demonstrated the anti-lipid accumulation and autophagy effects of EHD2 peptide at the cellular level

[0035] 1. EHD2 peptide promotes autophagy in HepG2 cells and reduces lipid accumulation

[0036] HepG2 treated with oleic acid (OA) were inoculated in 6-well culture plates, the cells were evenly plated, the cell density was observed under a microscope, the culture dish was placed in a cell culture incubator, and fresh culture medium was replaced as needed. The peptide eukaryotic expression vector and other control groups were transiently transfected into HepG2 using Lipofectamin2000 kit. Electron microscopy results showed that compared with the control group, the autophagosomes in the OA-treated HepG2 cells were significantly reduced, the fat vacuoles were increased, and the mitochondria were damaged. The results showed that compared with the empty control, the peptide eukaryotic expression experimental group significantly inhibited the lipid accumulation of HepG2 cells, such as Figure 2 This indicates that overexpression of the polypeptide promotes the autophagy level of HepG2 cells and can effectively inhibit cellular lipogenesis and lipid accumulation.

[0037] 2. Oil red staining showed that lipid accumulation in HepG2 cells was reduced after incorporation of EHD2 peptide

[0038] The HepG2 cells treated with oleic acid (OA) in step 1 were stained with oil red. The process was as follows: (1) discard the old culture medium and wash twice with PBS; (2) add 2 ml of paraformaldehyde to fix the cells for 30 minutes at room temperature, and then rinse with ddH2O water; (3) discard the paraformaldehyde, add an appropriate amount of modified oil red working solution and stain for 20 minutes in the dark; (4) discard the oil red working solution and soak in 60% isopropanol for a few seconds; (5) add 1 ml of PBS, wash twice, discard the PBS, and observe and take pictures under a microscope. Figure 3 As shown, oil red staining showed that the lipid accumulation of HepG2 cells after the incorporation of EHD2 polypeptide decreased oil red, indicating that the incorporation of EHD2 polypeptide significantly reversed the effect of lipid accumulation, was beneficial to inhibit lipid accumulation, and produced a lipid-clearing effect.

[0039] 3. WB experiments detected that EHD2 polypeptide inhibited the expression of lipid accumulation regulatory protein SREBP1.

[0040] Western blotting was used to compare the molecular protein levels of the four groups of proteins, which was carried out through a series of steps such as electrophoresis, membrane transfer, blocking, antibody incubation, and development. First, OA oleic acid was used to stimulate HepG2 cells to put the cells in an environment of lipid accumulation, and then on this basis, the control and EHD2 polypeptides were transduced into HepG2 cells respectively. Figure 4 As shown, it can be found that after transduction of EHD2 polypeptide, the SREBP1 protein level was significantly lower than that of the control group, indicating that the activation of its lipid accumulation pathway was significantly decreased, which can further promote a significant reduction in intracellular fat accumulation, suggesting that inhibiting lipid accumulation and improving fatty degeneration by incorporating this polypeptide may be a new treatment site for non-alcoholic fatty liver disease.

Claims

1. A gene encoding an EHD2 polypeptide, characterized in that: The amino acid sequence of the EHD2 polypeptide is shown in SEQ ID NO.1, and the DNA sequence of the gene is shown in SEQ ID NO.

2.

2. A vector of EHD2 polypeptide, characterized in that: The DNA sequence of the EHD2 polypeptide is connected to the PCMV-HA eukaryotic expression vector to construct a recombinant expression plasmid, namely the vector.

3. Use of an EHD2 polypeptide, a gene encoding an EHD2 polypeptide or a vector comprising an EHD2 polypeptide in the preparation of an anti-nonalcoholic fatty liver disease drug, wherein the amino acid sequence of the EHD2 polypeptide is shown in SEQ ID NO.1, and the DNA sequence of the gene is shown in SEQ ID NO.

2.

4. The use according to claim 3, characterized in that: The anti-nonalcoholic fatty liver drug is a drug that inhibits lipid synthesis in hepatocytes and promotes lipid metabolism by promoting HepG2 cell autophagy and / or inhibiting hepatocyte lipid accumulation.

Citation Information

Patent Citations

  • Interogatory cell-based assays for identifying drug-induced toxicity markers

    CN107449921A

Cited By

  • TIFIA-IA polypeptide as well as coding nucleic acid and medical application thereof

    CN118976125A

  • TIF-IA polypeptide, its encoding nucleic acid and pharmaceutical use

    CN118976125B